Accès ouvert
2026
article
OpenAlex
Pierre N. Tariot, Darren R. Gitelman, Ishtar Govia, Katherine A. Partrick et autres
Mild cognitive impairment and dementia are underrecognized in primary care, contributing to delayed diagnosis and limited access to care. Growing research has focused on improving cognitive evaluation in primary care, including the development of digital cognitive assessments (DCAs), which are emerging as …
us, gb
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Louisa I. Thompson, Barak Gaster, Dustin B. Hammers, Sol Fittipaldi et autres
The rising prevalence of mild cognitive impairment (MCI) and dementia, combined with persistent underdiagnosis, is driving an increased need for scalable cognitive assessment tools. Digital cognitive assessments (DCAs) offer a promising solution by addressing longstanding barriers to routine cognitive testing and diagnosis. …
us, ie, cl, ar, gb
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Jennifer Pettis, Lisa C. McGuire, Ben Tiede, Emily Scholler
Abstract The growing number of people with undiagnosed dementia underscores the urgent need to improve routine screening procedures for cognitive impairment in older adults. While health care continues to advance technologically, most traditional cognitive screening tools remain paper based. Emerging research suggests …
us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Karen Tracy, Julie K. Wood, Ben Tiede, Emily Scholler
Abstract Clinical research demonstrates the value of early detection of dementia, including dementia caused by Alzheimer’s disease (AD) and related disorders. Yet, timely and accurate diagnosis of AD in clinical practice remains challenging. The most widely used biomarkers to aid diagnosis of …
us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Michelle M. Mielke, Matthew Anderson, J. Wesson Ashford, Andreas Jeromin et autres
Diagnosing Alzheimer's disease (AD) poses significant challenges to health care, often resulting in delayed or inadequate patient care. The clinical integration of blood-based biomarkers (BBMs) for AD holds promise in enabling early detection of pathology and timely intervention. However, several critical considerations, …
us, se, ch, br, Kenya
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Michelle M. Mielke, Matthew Anderson, J. Wesson Ashford, Andreas Jeromin et autres
Blood-based biomarkers (BBM) for Alzheimer's disease (AD) are being increasingly used in clinical practice to support an AD diagnosis. In contrast to traditional diagnostic modalities, such as amyloid positron emission tomography and cerebrospinal fluid biomarkers, BBMs offer a more accessible and lower …
us, se, ch, br, Kenya
(code pays fourni par la source)
Accès ouvert
2024
review
OpenAlex
Suzanne E. Schindler, Douglas Galasko, Ana C. Pereira, Gil D. Rabinovici et autres
Anti-amyloid treatments for early symptomatic Alzheimer disease have recently become clinically available in some countries, which has greatly increased the need for biomarker confirmation of amyloid pathology. Blood biomarker (BBM) tests for amyloid pathology are more acceptable, accessible and scalable than amyloid …
us, es, ch, nl, se
(code pays fourni par la source)